Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
17 August 2021 | Story Dikgapane Makhetha | Photo Supplied
Bishop Billyboy Ramahlele (Director: Community Engagement), Napo Masheane (lead actress), and Troy Myeni (Director)

A short fiction film that was shot in Botshabelo and on the Bloemfontein Campus of the UFS, has once again shown the endless possibilities of engaged scholarship in the creative arts.

For this film project, engaged scholarship meant working with graduates / current students from the UFS on projects with a relevant and impactful theme for the broader community. The project was aimed at giving current or past students the opportunity to gain experience or share experience and to transfer skills in the area of filmmaking. 

The short fiction film, Leshano (The Lie), was directed by Mpendulo ‘Troy’ Myeni, a graduate of the UFS Film Programme, who also won an award at the Pan African Film Festival in the US for another of his short films.  Troy was also one of the three co-producers, along with Anton Fisher (a former employee of the UFS), who wrote the script, and Moeketsi Mphunye, a young filmmaker from Botshabelo.
Another notable UFS graduate who was central to the production, is Mbuyiselo Nqodi. He graduated with a BA in Drama and Theatre Arts and has since gone on to make a huge contribution to the performing arts in the Free State and South Africa. Mbuyiselo was the first assistant director of Leshano (The Lie) and had the unenviable job of keeping everything moving on set.  Other members of the production registered at the UFS, but never completed their studies. 

Bishop Billyboy Ramahlele, Director of Community Engagement at the UFS, said he was proud that the UFS could be part of this filmmaking project by making offices available as locations for the film and through the participation of distinguished graduates in key positions of the production.

“The UFS has much to offer young people as students, but also as graduates who seek to advance in their chosen careers. Through community engagement, these young people, whether students or graduates, can be inspired by working with professionals in various fields and gaining hands-on experience. They can then plough back into the community and the UFS.”

“This is the virtuous cycle of community engagement at a university. Students gain knowledge, then they gain inspiration and experience, and plough back into the UFS and broader community, instilling hope for future generations,” Bishop Ramahlele said. 

He added that the UFS would be mentioned in the credits of the film and in publicity and marketing of the film, profiling its reputation as a centre of creative excellence.

Leshano (The Lie) was filmed in Sesotho, with English subtitles, and deals with the important issue of corruption. The lead role is played by the acclaimed Napo Masheane who grew up in Qwaqwa, supported by well-known Free State actors Maria de Koker, Seipati Mpotoane, Ntsiki Ndzume, Vincent Tsoametsi, Pesa Pheko, and Shayne Nketsi. 

Several young, aspiring filmmakers from across the Free State were recruited for the project. It was their first time on the set of a film production, whether as make-up artists, behind the scenes photographers, unit production managers, wardrobe assistants, or location scouts. 

With a strong line-up of women in the lead roles, the film will be released later in August during Women’s Month. 

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept